
Stifel's Head of Therapeutics Research Paul Matteis shares his take on biotech and discusses companies he covers that have been in the news
Notas del episodio
He discusses Biogen, Alnylam, Xenon, and Compass Pathways

He discusses Biogen, Alnylam, Xenon, and Compass Pathways